Global X - S&P Biotech ETF (ASX: CURE.AX) Stock Competitors & Peer Comparison
See CURE.AX's competitors and their performance on the ASX and across the wider stock market.
Peer Comparison Table: Asset Management - Global Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CURE.AX and its ASX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CURE.AX | A$78.32 | +0.12% | 41.8M | N/A | N/A | N/A |
| VAS.AX | A$113.94 | +1.24% | 25.9B | 21.65 | A$5.23 | +2.87% |
| IVV.AX | A$71.40 | +0.14% | 14.4B | 27.71 | A$2.57 | +1.04% |
| VGS.AX | A$160.32 | +0.16% | 13.4B | 24.88 | A$6.42 | +1.28% |
| VTS.AX | A$528.51 | +0.10% | 9.7B | N/A | N/A | +1.08% |
| IOZ.AX | A$36.85 | +1.35% | 9.1B | 21.77 | A$1.68 | +3.31% |
| QUAL.AX | A$61.85 | +0.52% | 9B | 27.50 | A$2.24 | +3.50% |
| VGAD.AX | A$131.87 | +0.34% | 7.6B | 24.51 | A$5.37 | +2.23% |
| STW.AX | A$82.12 | +1.27% | 6.6B | 21.70 | A$3.76 | +3.57% |
| IOO.AX | A$197.00 | -0.36% | 5.7B | 27.06 | A$7.25 | +1.21% |
Stock Comparison
Vanguard Australian Shares Index ETF (ASX: VAS.AX)
CURE.AX vs VAS.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VAS.AX has a market cap of 25.9B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VAS.AX trades at A$113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VAS.AX's P/E ratio is 21.65. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VAS.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VAS.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VAS.AX's competition here
iShares S&P 500 ETF (ASX: IVV.AX)
CURE.AX vs IVV.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IVV.AX has a market cap of 14.4B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IVV.AX trades at A$71.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IVV.AX's P/E ratio is 27.71. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IVV.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IVV.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IVV.AX's competition here
Vanguard MSCI Index International Shares ETF (ASX: VGS.AX)
CURE.AX vs VGS.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VGS.AX has a market cap of 13.4B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VGS.AX trades at A$160.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VGS.AX's P/E ratio is 24.88. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VGS.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VGS.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VGS.AX's competition here
Vanguard U.S. Total Market Shares Index ETF (ASX: VTS.AX)
CURE.AX vs VTS.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VTS.AX has a market cap of 9.7B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VTS.AX trades at A$528.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VTS.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VTS.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VTS.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VTS.AX's competition here
iShares Core S&P/ASX 200 ETF (ASX: IOZ.AX)
CURE.AX vs IOZ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IOZ.AX has a market cap of 9.1B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IOZ.AX trades at A$36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IOZ.AX's P/E ratio is 21.77. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IOZ.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to IOZ.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IOZ.AX's competition here
VanEck - MSCI International Quality ETF (ASX: QUAL.AX)
CURE.AX vs QUAL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, QUAL.AX has a market cap of 9B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while QUAL.AX trades at A$61.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas QUAL.AX's P/E ratio is 27.50. In terms of profitability, CURE.AX's ROE is +0.00%, compared to QUAL.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to QUAL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check QUAL.AX's competition here
Vanguard MSCI Index International Shares (Hedged) ETF (ASX: VGAD.AX)
CURE.AX vs VGAD.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VGAD.AX has a market cap of 7.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VGAD.AX trades at A$131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VGAD.AX's P/E ratio is 24.51. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VGAD.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VGAD.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VGAD.AX's competition here
State Street SPDR S&P/ASX 200 ETF (ASX: STW.AX)
CURE.AX vs STW.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, STW.AX has a market cap of 6.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while STW.AX trades at A$82.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas STW.AX's P/E ratio is 21.70. In terms of profitability, CURE.AX's ROE is +0.00%, compared to STW.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to STW.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check STW.AX's competition here
iShares Global 100 ETF (ASX: IOO.AX)
CURE.AX vs IOO.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IOO.AX has a market cap of 5.7B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IOO.AX trades at A$197.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IOO.AX's P/E ratio is 27.06. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IOO.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IOO.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IOO.AX's competition here
iShares S&P 500 (AUD Hedged) ETF (ASX: IHVV.AX)
CURE.AX vs IHVV.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IHVV.AX has a market cap of 4.2B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IHVV.AX trades at A$67.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IHVV.AX's P/E ratio is 26.61. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IHVV.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IHVV.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IHVV.AX's competition here
Vanguard Diversified High Growth Index ETF (ASX: VDHG.AX)
CURE.AX vs VDHG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VDHG.AX has a market cap of 4.1B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VDHG.AX trades at A$77.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VDHG.AX's P/E ratio is 22.29. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VDHG.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to VDHG.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VDHG.AX's competition here
BetaShares - Global Sustainability Leaders ETF (ASX: ETHI.AX)
CURE.AX vs ETHI.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ETHI.AX has a market cap of 3.9B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ETHI.AX trades at A$16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ETHI.AX's P/E ratio is 22.26. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ETHI.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to ETHI.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check ETHI.AX's competition here
VanEck - Australian Equal Weight ETF (ASX: MVW.AX)
CURE.AX vs MVW.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MVW.AX has a market cap of 3.4B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MVW.AX trades at A$39.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MVW.AX's P/E ratio is 22.87. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MVW.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to MVW.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check MVW.AX's competition here
VanEck - MSCI International Quality (AUD Hedged) ETF (ASX: QHAL.AX)
CURE.AX vs QHAL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, QHAL.AX has a market cap of 2.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while QHAL.AX trades at A$56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas QHAL.AX's P/E ratio is 27.43. In terms of profitability, CURE.AX's ROE is +0.00%, compared to QHAL.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to QHAL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check QHAL.AX's competition here
VanEck - FTSE Global Infrastructure (AUD Hedged) ETF (ASX: IFRA.AX)
CURE.AX vs IFRA.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IFRA.AX has a market cap of 2B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IFRA.AX trades at A$25.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IFRA.AX's P/E ratio is 21.17. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IFRA.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IFRA.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IFRA.AX's competition here
Vanguard FTSE Emerging Markets Shares ETF (ASX: VGE.AX)
CURE.AX vs VGE.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VGE.AX has a market cap of 2B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VGE.AX trades at A$92.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VGE.AX's P/E ratio is 10.66. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VGE.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VGE.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VGE.AX's competition here
iShares MSCI Emerging Markets ETF (ASX: IEM.AX)
CURE.AX vs IEM.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IEM.AX has a market cap of 1.9B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IEM.AX trades at A$93.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IEM.AX's P/E ratio is 17.26. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IEM.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to IEM.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check IEM.AX's competition here
iShares Core FTSE Global Infrastructure (AUD Hedged) ETF (ASX: GLIN.AX)
CURE.AX vs GLIN.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, GLIN.AX has a market cap of 1.7B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while GLIN.AX trades at A$30.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas GLIN.AX's P/E ratio is 20.25. In terms of profitability, CURE.AX's ROE is +0.00%, compared to GLIN.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to GLIN.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check GLIN.AX's competition here
iShares MSCI Japan ETF (ASX: IJP.AX)
CURE.AX vs IJP.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IJP.AX has a market cap of 1.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IJP.AX trades at A$131.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IJP.AX's P/E ratio is 19.34. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IJP.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to IJP.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IJP.AX's competition here
Vanguard Diversified Growth Index ETF (ASX: VDGR.AX)
CURE.AX vs VDGR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VDGR.AX has a market cap of 1.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VDGR.AX trades at A$68.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VDGR.AX's P/E ratio is 22.03. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VDGR.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to VDGR.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VDGR.AX's competition here
PM Capital Global Opportunities Fund Limited (ASX: PGF.AX)
CURE.AX vs PGF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, PGF.AX has a market cap of 1.6B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while PGF.AX trades at A$3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas PGF.AX's P/E ratio is 3.43. In terms of profitability, CURE.AX's ROE is +0.00%, compared to PGF.AX's ROE of +0.20%. Regarding short-term risk, CURE.AX is more volatile compared to PGF.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check PGF.AX's competition here
Vanguard Ethically Conscious International Shares Index ETF (ASX: VESG.AX)
CURE.AX vs VESG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VESG.AX has a market cap of 1.5B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VESG.AX trades at A$118.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VESG.AX's P/E ratio is 24.57. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VESG.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VESG.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VESG.AX's competition here
Navigator Global Investments Limited (ASX: NGI.AX)
CURE.AX vs NGI.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, NGI.AX has a market cap of 1.5B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while NGI.AX trades at A$2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas NGI.AX's P/E ratio is 18.58. In terms of profitability, CURE.AX's ROE is +0.00%, compared to NGI.AX's ROE of +0.02%. Regarding short-term risk, CURE.AX is less volatile compared to NGI.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check NGI.AX's competition here
Vanguard Global Value Equity Active ETF (ASX: VVLU.AX)
CURE.AX vs VVLU.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VVLU.AX has a market cap of 1.3B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VVLU.AX trades at A$82.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VVLU.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VVLU.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VVLU.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VVLU.AX's competition here
BetaShares - FTSE RAFI Australia 200 ETF (ASX: QOZ.AX)
CURE.AX vs QOZ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, QOZ.AX has a market cap of 1.3B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while QOZ.AX trades at A$19.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas QOZ.AX's P/E ratio is 21.01. In terms of profitability, CURE.AX's ROE is +0.00%, compared to QOZ.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to QOZ.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check QOZ.AX's competition here
Vanguard MSCI Australian Small Companies Index ETF (ASX: VSO.AX)
CURE.AX vs VSO.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VSO.AX has a market cap of 1.2B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VSO.AX trades at A$76.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VSO.AX's P/E ratio is 20.31. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VSO.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to VSO.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check VSO.AX's competition here
iShares Europe ETF (ASX: IEU.AX)
CURE.AX vs IEU.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IEU.AX has a market cap of 1.2B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IEU.AX trades at A$99.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IEU.AX's P/E ratio is 17.76. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IEU.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IEU.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IEU.AX's competition here
BetaShares - S&P 500 Equal Weight ETF (ASX: QUS.AX)
CURE.AX vs QUS.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, QUS.AX has a market cap of 1.1B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while QUS.AX trades at A$56.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas QUS.AX's P/E ratio is 23.00. In terms of profitability, CURE.AX's ROE is +0.00%, compared to QUS.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to QUS.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check QUS.AX's competition here
BetaShares - Australian Sustainability Leaders ETF (ASX: FAIR.AX)
CURE.AX vs FAIR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, FAIR.AX has a market cap of 1.1B. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while FAIR.AX trades at A$19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas FAIR.AX's P/E ratio is 21.04. In terms of profitability, CURE.AX's ROE is +0.00%, compared to FAIR.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to FAIR.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check FAIR.AX's competition here
Vanguard Diversified Balanced Index ETF (ASX: VDBA.AX)
CURE.AX vs VDBA.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VDBA.AX has a market cap of 950.2M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VDBA.AX trades at A$60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VDBA.AX's P/E ratio is 21.76. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VDBA.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to VDBA.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VDBA.AX's competition here
VanEck - Australian Resources ETF (ASX: MVR.AX)
CURE.AX vs MVR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MVR.AX has a market cap of 809M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MVR.AX trades at A$50.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MVR.AX's P/E ratio is 22.25. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MVR.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to MVR.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check MVR.AX's competition here
WAM Global Limited (ASX: WGB.AX)
CURE.AX vs WGB.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WGB.AX has a market cap of 776.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WGB.AX trades at A$2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WGB.AX's P/E ratio is 5.56. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WGB.AX's ROE of -0.04%. Regarding short-term risk, CURE.AX is less volatile compared to WGB.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check WGB.AX's competition here
iShares S&P/ASX 20 ETF (ASX: ILC.AX)
CURE.AX vs ILC.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ILC.AX has a market cap of 765.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ILC.AX trades at A$35.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ILC.AX's P/E ratio is 22.02. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ILC.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to ILC.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check ILC.AX's competition here
VanEck - MSCI Multifactor Emerging Markets Equity ETF (ASX: EMKT.AX)
CURE.AX vs EMKT.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, EMKT.AX has a market cap of 755.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while EMKT.AX trades at A$35.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas EMKT.AX's P/E ratio is 12.53. In terms of profitability, CURE.AX's ROE is +0.00%, compared to EMKT.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to EMKT.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check EMKT.AX's competition here
BetaShares - Australian Ex-20 Portfolio Diversifier ETF (ASX: EX20.AX)
CURE.AX vs EX20.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, EX20.AX has a market cap of 720.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while EX20.AX trades at A$23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas EX20.AX's P/E ratio is 20.80. In terms of profitability, CURE.AX's ROE is +0.00%, compared to EX20.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to EX20.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check EX20.AX's competition here
State Street SPDR S&P/ASX 50 ETF (ASX: SFY.AX)
CURE.AX vs SFY.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, SFY.AX has a market cap of 712.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while SFY.AX trades at A$79.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas SFY.AX's P/E ratio is 21.80. In terms of profitability, CURE.AX's ROE is +0.00%, compared to SFY.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to SFY.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check SFY.AX's competition here
Future Generation Global Limited (ASX: FGG.AX)
CURE.AX vs FGG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, FGG.AX has a market cap of 663.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while FGG.AX trades at A$1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas FGG.AX's P/E ratio is 13.75. In terms of profitability, CURE.AX's ROE is +0.00%, compared to FGG.AX's ROE of +0.08%. Regarding short-term risk, CURE.AX is less volatile compared to FGG.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check FGG.AX's competition here
Vanguard Global Infrastructure Index ETF (ASX: VBLD.AX)
CURE.AX vs VBLD.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VBLD.AX has a market cap of 648M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VBLD.AX trades at A$74.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VBLD.AX's P/E ratio is 20.22. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VBLD.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to VBLD.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VBLD.AX's competition here
iShares S&P Mid-Cap ETF (ASX: IJH.AX)
CURE.AX vs IJH.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IJH.AX has a market cap of 517.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IJH.AX trades at A$53.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IJH.AX's P/E ratio is 22.43. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IJH.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to IJH.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IJH.AX's competition here
State Street SPDR Dow Jones Global Real Estate ESG Tilted ETF (ASX: DJRE.AX)
CURE.AX vs DJRE.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, DJRE.AX has a market cap of 517.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while DJRE.AX trades at A$22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas DJRE.AX's P/E ratio is 21.77. In terms of profitability, CURE.AX's ROE is +0.00%, compared to DJRE.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to DJRE.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check DJRE.AX's competition here
iShares China Large-Cap ETF (ASX: IZZ.AX)
CURE.AX vs IZZ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IZZ.AX has a market cap of 511.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IZZ.AX trades at A$48.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IZZ.AX's P/E ratio is 10.17. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IZZ.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to IZZ.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check IZZ.AX's competition here
VanEck - S&P/ASX MidCap ETF (ASX: MVE.AX)
CURE.AX vs MVE.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MVE.AX has a market cap of 504.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MVE.AX trades at A$46.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MVE.AX's P/E ratio is 30.07. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MVE.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to MVE.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check MVE.AX's competition here
Argo Global Listed Infrastructure Limited (ASX: ALI.AX)
CURE.AX vs ALI.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ALI.AX has a market cap of 493.6M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ALI.AX trades at A$2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ALI.AX's P/E ratio is 28.09. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ALI.AX's ROE of +0.08%. Regarding short-term risk, CURE.AX is more volatile compared to ALI.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check ALI.AX's competition here
BetaShares - FTSE 100 ETF (ASX: F100.AX)
CURE.AX vs F100.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, F100.AX has a market cap of 425.6M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while F100.AX trades at A$15.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas F100.AX's P/E ratio is 18.13. In terms of profitability, CURE.AX's ROE is +0.00%, compared to F100.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to F100.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check F100.AX's competition here
Russell Investments Australian Responsible Investment ETF (ASX: RARI.AX)
CURE.AX vs RARI.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, RARI.AX has a market cap of 407.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while RARI.AX trades at A$29.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas RARI.AX's P/E ratio is 20.18. In terms of profitability, CURE.AX's ROE is +0.00%, compared to RARI.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to RARI.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check RARI.AX's competition here
State Street SPDR S&P World ex Australia Carbon Aware (Hedged) ETF (ASX: WXHG.AX)
CURE.AX vs WXHG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WXHG.AX has a market cap of 400.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WXHG.AX trades at A$29.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WXHG.AX's P/E ratio is 21.82. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WXHG.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to WXHG.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check WXHG.AX's competition here
WCM Quality Global Growth ETF (Quoted Managed) (ASX: WCMQ.AX)
CURE.AX vs WCMQ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WCMQ.AX has a market cap of 380.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WCMQ.AX trades at A$10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WCMQ.AX's P/E ratio is 31.97. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WCMQ.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to WCMQ.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check WCMQ.AX's competition here
BetaShares - Japan Currency Hedged ETF (ASX: HJPN.AX)
CURE.AX vs HJPN.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, HJPN.AX has a market cap of 338.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while HJPN.AX trades at A$30.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas HJPN.AX's P/E ratio is 20.69. In terms of profitability, CURE.AX's ROE is +0.00%, compared to HJPN.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to HJPN.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check HJPN.AX's competition here
BetaShares - Global Robotics and Artificial Intelligence ETF (ASX: RBTZ.AX)
CURE.AX vs RBTZ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, RBTZ.AX has a market cap of 325.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while RBTZ.AX trades at A$14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas RBTZ.AX's P/E ratio is 33.57. In terms of profitability, CURE.AX's ROE is +0.00%, compared to RBTZ.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to RBTZ.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check RBTZ.AX's competition here
Vanguard Diversified Conservative Index ETF (ASX: VDCO.AX)
CURE.AX vs VDCO.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VDCO.AX has a market cap of 304.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VDCO.AX trades at A$55.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VDCO.AX's P/E ratio is 21.50. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VDCO.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to VDCO.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VDCO.AX's competition here
Global X - Morningstar Global Technology ETF (ASX: TECH.AX)
CURE.AX vs TECH.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, TECH.AX has a market cap of 280.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while TECH.AX trades at A$119.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas TECH.AX's P/E ratio is 34.68. In terms of profitability, CURE.AX's ROE is +0.00%, compared to TECH.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to TECH.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check TECH.AX's competition here
Staude Capital Global Value Fund Limited (ASX: GVF.AX)
CURE.AX vs GVF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, GVF.AX has a market cap of 276.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while GVF.AX trades at A$1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas GVF.AX's P/E ratio is 16.41. In terms of profitability, CURE.AX's ROE is +0.00%, compared to GVF.AX's ROE of +0.06%. Regarding short-term risk, CURE.AX is more volatile compared to GVF.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check GVF.AX's competition here
VanEck - Australian Banks ETF (ASX: MVB.AX)
CURE.AX vs MVB.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MVB.AX has a market cap of 272.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MVB.AX trades at A$42.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MVB.AX's P/E ratio is 19.57. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MVB.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to MVB.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check MVB.AX's competition here
VanEck - MSCI International Sustainable Equity ETF (ASX: ESGI.AX)
CURE.AX vs ESGI.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ESGI.AX has a market cap of 262.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ESGI.AX trades at A$37.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ESGI.AX's P/E ratio is 21.57. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ESGI.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to ESGI.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check ESGI.AX's competition here
iShares MSCI South Korea ETF (ASX: IKO.AX)
CURE.AX vs IKO.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IKO.AX has a market cap of 252.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IKO.AX trades at A$246.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IKO.AX's P/E ratio is 17.29. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IKO.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to IKO.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check IKO.AX's competition here
VanEck - MSCI Australian Sustainable Equity ETF (ASX: GRNV.AX)
CURE.AX vs GRNV.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, GRNV.AX has a market cap of 247M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while GRNV.AX trades at A$32.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas GRNV.AX's P/E ratio is 23.94. In terms of profitability, CURE.AX's ROE is +0.00%, compared to GRNV.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to GRNV.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check GRNV.AX's competition here
BetaShares - Global Defence ETF (ASX: ARMR.AX)
CURE.AX vs ARMR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ARMR.AX has a market cap of 234.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ARMR.AX trades at A$23.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ARMR.AX's P/E ratio is 29.20. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ARMR.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to ARMR.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check ARMR.AX's competition here
Tribeca Global Natural Resources Limited (ASX: TGF.AX)
CURE.AX vs TGF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, TGF.AX has a market cap of 210.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while TGF.AX trades at A$2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas TGF.AX's P/E ratio is 2.61. In terms of profitability, CURE.AX's ROE is +0.00%, compared to TGF.AX's ROE of +0.43%. Regarding short-term risk, CURE.AX is more volatile compared to TGF.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check TGF.AX's competition here
BetaShares - Global Banks Currency Hedged ETF (ASX: BNKS.AX)
CURE.AX vs BNKS.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, BNKS.AX has a market cap of 176.2M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while BNKS.AX trades at A$14.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas BNKS.AX's P/E ratio is 13.57. In terms of profitability, CURE.AX's ROE is +0.00%, compared to BNKS.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to BNKS.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check BNKS.AX's competition here
BetaShares - Global Healthcare Currency Hedged ETF (ASX: DRUG.AX)
CURE.AX vs DRUG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, DRUG.AX has a market cap of 170.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while DRUG.AX trades at A$9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas DRUG.AX's P/E ratio is 25.01. In terms of profitability, CURE.AX's ROE is +0.00%, compared to DRUG.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to DRUG.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check DRUG.AX's competition here
BetaShares - India Quality ETF (ASX: IIND.AX)
CURE.AX vs IIND.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, IIND.AX has a market cap of 169.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while IIND.AX trades at A$9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas IIND.AX's P/E ratio is 27.52. In terms of profitability, CURE.AX's ROE is +0.00%, compared to IIND.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to IIND.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check IIND.AX's competition here
Betashares Global Energy Companies Currency Hedged ETF (ASX: FUEL.AX)
CURE.AX vs FUEL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, FUEL.AX has a market cap of 168.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while FUEL.AX trades at A$8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas FUEL.AX's P/E ratio is 19.98. In terms of profitability, CURE.AX's ROE is +0.00%, compared to FUEL.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to FUEL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check FUEL.AX's competition here
Schroder Global Core Fund - Active ETF (ASX: CORE.AX)
CURE.AX vs CORE.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, CORE.AX has a market cap of 154.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while CORE.AX trades at A$11.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas CORE.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to CORE.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to CORE.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check CORE.AX's competition here
iShares S&P/ASX Small Ordinaries ETF (ASX: ISO.AX)
CURE.AX vs ISO.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ISO.AX has a market cap of 138.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ISO.AX trades at A$5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ISO.AX's P/E ratio is 17.97. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ISO.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to ISO.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check ISO.AX's competition here
Global Data Centre Group (ASX: GDC.AX)
CURE.AX vs GDC.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, GDC.AX has a market cap of 110.1M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while GDC.AX trades at A$1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas GDC.AX's P/E ratio is 2.74. In terms of profitability, CURE.AX's ROE is +0.00%, compared to GDC.AX's ROE of +0.07%. Regarding short-term risk, CURE.AX is more volatile compared to GDC.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check GDC.AX's competition here
BetaShares - Europe Currency Hedged ETF (ASX: HEUR.AX)
CURE.AX vs HEUR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, HEUR.AX has a market cap of 90.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while HEUR.AX trades at A$18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas HEUR.AX's P/E ratio is 20.48. In terms of profitability, CURE.AX's ROE is +0.00%, compared to HEUR.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to HEUR.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check HEUR.AX's competition here
Global X - Physical Platinum Structured (ASX: ETPMPT.AX)
CURE.AX vs ETPMPT.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, ETPMPT.AX has a market cap of 84.4M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while ETPMPT.AX trades at A$237.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas ETPMPT.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to ETPMPT.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to ETPMPT.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check ETPMPT.AX's competition here
iShares MSCI World ex Australia Minimum Volatility ETF (ASX: WVOL.AX)
CURE.AX vs WVOL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WVOL.AX has a market cap of 81.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WVOL.AX trades at A$46.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WVOL.AX's P/E ratio is 23.45. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WVOL.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to WVOL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check WVOL.AX's competition here
BetaShares - Australian Financials Sector ETF (ASX: QFN.AX)
CURE.AX vs QFN.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, QFN.AX has a market cap of 80.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while QFN.AX trades at A$17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas QFN.AX's P/E ratio is 19.11. In terms of profitability, CURE.AX's ROE is +0.00%, compared to QFN.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to QFN.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check QFN.AX's competition here
BetaShares - Global Agriculture Companies Currency Hedged ETF (ASX: FOOD.AX)
CURE.AX vs FOOD.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, FOOD.AX has a market cap of 76M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while FOOD.AX trades at A$8.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas FOOD.AX's P/E ratio is 18.28. In terms of profitability, CURE.AX's ROE is +0.00%, compared to FOOD.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to FOOD.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check FOOD.AX's competition here
VanEck - China New Economy ETF (ASX: CNEW.AX)
CURE.AX vs CNEW.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, CNEW.AX has a market cap of 75.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while CNEW.AX trades at A$7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas CNEW.AX's P/E ratio is 23.88. In terms of profitability, CURE.AX's ROE is +0.00%, compared to CNEW.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to CNEW.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check CNEW.AX's competition here
BetaShares - Australian Equities Bear Complex ETF (ASX: BEAR.AX)
CURE.AX vs BEAR.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, BEAR.AX has a market cap of 51.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while BEAR.AX trades at A$7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas BEAR.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to BEAR.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to BEAR.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check BEAR.AX's competition here
BetaShares - Managed Risk Global Shares Complex ETF (ASX: WRLD.AX)
CURE.AX vs WRLD.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WRLD.AX has a market cap of 50.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WRLD.AX trades at A$23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WRLD.AX's P/E ratio is 24.15. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WRLD.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to WRLD.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check WRLD.AX's competition here
Fat Prophets Global Contrarian Fund Ltd (ASX: FPC.AX)
CURE.AX vs FPC.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, FPC.AX has a market cap of 43.9M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while FPC.AX trades at A$1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas FPC.AX's P/E ratio is 2.38. In terms of profitability, CURE.AX's ROE is +0.00%, compared to FPC.AX's ROE of +0.36%. Regarding short-term risk, CURE.AX is less volatile compared to FPC.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check FPC.AX's competition here
State Street SPDR S&P/ASX 200 Financials EX A-REIT ETF (ASX: OZF.AX)
CURE.AX vs OZF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, OZF.AX has a market cap of 43.3M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while OZF.AX trades at A$29.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas OZF.AX's P/E ratio is 20.29. In terms of profitability, CURE.AX's ROE is +0.00%, compared to OZF.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to OZF.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check OZF.AX's competition here
VanEck - FTSE China A50 ETF (ASX: CETF.AX)
CURE.AX vs CETF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, CETF.AX has a market cap of 37.8M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while CETF.AX trades at A$60.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas CETF.AX's P/E ratio is 14.05. In terms of profitability, CURE.AX's ROE is +0.00%, compared to CETF.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to CETF.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check CETF.AX's competition here
UBS IQ MSCI World ex Australia Ethical ETF (ASX: UBW.AX)
CURE.AX vs UBW.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, UBW.AX has a market cap of 33.4M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while UBW.AX trades at A$28.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas UBW.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to UBW.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to UBW.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check UBW.AX's competition here
Global Masters Fund Limited (ASX: GFL.AX)
CURE.AX vs GFL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, GFL.AX has a market cap of 33.2M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while GFL.AX trades at A$2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas GFL.AX's P/E ratio is 77.98. In terms of profitability, CURE.AX's ROE is +0.00%, compared to GFL.AX's ROE of -0.03%. Regarding short-term risk, CURE.AX is more volatile compared to GFL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check GFL.AX's competition here
State Street SPDR S&P Emerging Markets Carbon Aware ETF (ASX: WEMG.AX)
CURE.AX vs WEMG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, WEMG.AX has a market cap of 31.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while WEMG.AX trades at A$28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas WEMG.AX's P/E ratio is 15.36. In terms of profitability, CURE.AX's ROE is +0.00%, compared to WEMG.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to WEMG.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check WEMG.AX's competition here
iShares Edge MSCI Australia Minimum Volatility ETF (ASX: MVOL.AX)
CURE.AX vs MVOL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MVOL.AX has a market cap of 30.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MVOL.AX trades at A$36.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MVOL.AX's P/E ratio is 21.15. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MVOL.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to MVOL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check MVOL.AX's competition here
Vanguard Global Minimum Volatility Active ETF (ASX: VMIN.AX)
CURE.AX vs VMIN.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, VMIN.AX has a market cap of 16.5M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while VMIN.AX trades at A$62.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas VMIN.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to VMIN.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to VMIN.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check VMIN.AX's competition here
Associate Global Partners Limited (ASX: APL.AX)
CURE.AX vs APL.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, APL.AX has a market cap of 15.7M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while APL.AX trades at A$0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas APL.AX's P/E ratio is 54.19. In terms of profitability, CURE.AX's ROE is +0.00%, compared to APL.AX's ROE of +0.03%. Regarding short-term risk, CURE.AX is more volatile compared to APL.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check APL.AX's competition here
UBS IQ MSCI Asia APEX 50 Ethical ETF (ASX: UBP.AX)
CURE.AX vs UBP.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, UBP.AX has a market cap of 6.6M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while UBP.AX trades at A$28.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas UBP.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to UBP.AX's ROE of N/A. Regarding short-term risk, CURE.AX is less volatile compared to UBP.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check UBP.AX's competition here
UBS IQ MSCI Japan Ethical ETF (ASX: UBJ.AX)
CURE.AX vs UBJ.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, UBJ.AX has a market cap of 3M. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while UBJ.AX trades at A$23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas UBJ.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to UBJ.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is more volatile compared to UBJ.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check UBJ.AX's competition here
Magellan Global Fund (ASX: MGF.AX)
CURE.AX vs MGF.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, MGF.AX has a market cap of 0. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while MGF.AX trades at A$2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas MGF.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to MGF.AX's ROE of N/A. Regarding short-term risk, CURE.AX is more volatile compared to MGF.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check MGF.AX's competition here
Associate Global Partners Limited (ASX: CGA.AX)
CURE.AX vs CGA.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, CGA.AX has a market cap of 0. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while CGA.AX trades at A$0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas CGA.AX's P/E ratio is -29.33. In terms of profitability, CURE.AX's ROE is +0.00%, compared to CGA.AX's ROE of -0.11%. Regarding short-term risk, CURE.AX is more volatile compared to CGA.AX. This indicates higher risk in terms of short-term price fluctuations for CURE.AX.Check CGA.AX's competition here
Hyperion Global Growth Companies Fund (ASX: HYGG.AX)
CURE.AX vs HYGG.AX Comparison August 2026
Global X - S&P Biotech ETF (ASX: CURE.AX) plays a significant role within the Financial Services sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CURE.AX stands at 41.8M. In comparison, HYGG.AX has a market cap of 0. Regarding current trading prices, CURE.AX is priced at A$78.32 on the ASX, while HYGG.AX trades at A$5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CURE.AX currently has a P/E ratio of N/A, whereas HYGG.AX's P/E ratio is N/A. In terms of profitability, CURE.AX's ROE is +0.00%, compared to HYGG.AX's ROE of +0.00%. Regarding short-term risk, CURE.AX is less volatile compared to HYGG.AX. This indicates lower risk in terms of short-term price fluctuations for CURE.AX.Check HYGG.AX's competition here